Intra-Cellular Therapies, Inc.ITCI
時価総額
$134.3億
PER
精神疾患向けのバイオ医薬品の有力企業。主力製品CAPLYTAを米国で商業販売、2024年に営業担当を約150人増員。2025年1月10日にジョンソン・エンド・ジョンソンと合併契約、1株132ドルで買収予定。従業員数860人（2025年2月1日）で米国中心に展開。
| 2013年 3月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Net loss | - | - | - | - | - | - | -155,127,411 | -147,722,178 | -227,005,663 | -284,125,666 | -256 | -140 | -75 |
| Depreciation | - | 23,249 | 25,481 | 139,626 | 196,872 | 213,872 | 368,673 | 477,121 | 528,118 | 1 | 1 | 1 | 1 |
| Share-based compensation | - | 391,393 | 4 | 11 | 15 | 15 | 17 | 21 | 24 | 34 | 43 | 53 | 64 |
| Stock issued for services | - | - | 176,085 | 182,599 | 233,772 | 190,885 | 192,530 | 194,205 | 214,103 | 178,534 | 0 | 0 | 0 |
| Amortization of premiums and accretion of discounts on investment securities, net | - | - | -297,223 | -712,675 | -544,354 | -429,839 | 943,239 | 1 | 648,248 | 4 | -0 | 8 | 9 |
| Accounts receivable, net | - | 35,889 | -284,715 | -20,943 | 63,679 | -94,339 | - | - | 11 | 9 | 55 | 39 | 52 |
| Inventory | - | - | - | - | - | - | - | - | 7 | 891,741 | 16 | 26 | 15 |
| Prepaid expenses and other assets | - | 574,341 | 466,099 | 7 | -4,016,164 | 879,200 | 3 | -1,465,384 | 8 | 11 | 20 | 4 | 68 |
| Accounts payable | 26,170 | 3 | -1,342,302 | -419,860 | 2 | 2 | 8 | -6,536,036 | -1,923,199 | 3 | 2 | 1 | 15 |
| Accrued and other current liabilities | - | - | - | - | - | - | - | - | 198,036 | 12 | 9 | 8 | 37 |
| Accrued customer programs | - | - | - | - | - | - | - | - | - | - | -20 | -28 | -22 |
| Accrued employee benefits | - | 3 | 5 | -3,873,692 | 2 | 1 | 14 | 3 | - | - | 2 | 4 | 7 |
| Lease liabilities, net | - | - | - | - | - | - | - | - | - | - | - | -1 | -0 |
| Net cash used in operating activities | -5,930 | - | - | - | - | - | -118,169,113 | -127,983,241 | -230,072,845 | -259,543,485 | -270 | -124 | -73 |
| Purchases of investments | - | - | 104 | 514 | 396 | 521 | 271 | 81 | 756 | 225 | 759 | 415 | 740 |
| Maturities of investments | - | 2 | 37 | 153 | 488 | 429 | 406 | 259 | 276 | 505 | 632 | 521 | 405 |
| Purchases of property and equipment | - | 33,255 | 11,762 | 860,595 | 48,964 | 723,429 | 391,268 | 700,395 | 266,724 | 325,738 | 1 | 0 | 0 |
| Net cash (used in) provided by investing activities | - | - | - | - | - | - | 135 | 177 | -480,295,000 | 280 | -128 | 106 | -335 |
| Proceeds of public offerings, net | 10,000 | - | 116 | 450 | - | 162 | - | - | 653 | - | 434 | - | 543 |
| Proceeds from Stock Options Exercised | - | 332,938 | 162,980 | 653,046 | 477,734 | 285,160 | 674,206 | 3 | 11 | 12 | 21 | 18 | 24 |
| Net cash provided by financing activities | 10,000 | - | - | - | - | - | 685,188 | 3 | 664 | 12 | 455 | 18 | 568 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | - | - | - | - | - | - | 17 | 53 | -46,190,916 | 32 | 57 | -1 | 159 |
| Income Taxes Paid | - | 31,437 | 44,998 | - | 1,000,000 | - | 1,600 | 1,600 | 1,600 | 5,631 | 0 | 0 | 2 |
| Right of use assets under operating leases | - | - | - | - | - | - | - | - | - | - | - | - | 3 |